News & articles

Cancer is such a powerful word that it is often referred to as “The Big C” and comes with a loaded associated vocabulary, including words that can have both empowering or disturbing triggers, depending on the individual hearing it.   Not many people go through life without being touched by cancer in some way. This means… Read More »Cancer words matter

While cardiovascular events often accompany MPNs and contribute significantly to morbidity and mortality, the reasons remained unclear until research offered some insight in recent years.  Greater understanding about why and how blood cancers have connections to cardiovascular complications lays the groundwork to using this information to better assess and manage risk factors in MPN patients,… Read More »Cardiovascular Risk and MPNs

Thrive Award Spotlight: John Crispino, St. Jude Children’s Research HospitalCo-PI – Ayalew Tefferi, Mayo Clinic, MN Aberrant Megakaryopoiesis in the MPNs According to Leukemia & Lymphoma Society, although MPN patients can be stable for decades, they face a significant risk of having their disease advance to a more immediately life-threatening blood cancer, acute myeloid leukemia… Read More »How MPNs progress to AML and how to stop it

Kyle Bonder                                                                                                           … Read More »Caregiver Brings Unique Perspective to MPNRF Patient Impact Council

  Shannon Elf, PhD,    University of Utah  Huntsman Cancer Institute The metabolic landscape of MPNs is an extremely understudied area in the field. Solid tumor treatment has benefited tremendously from studying cellular metabolism in a number of cancers, and Dr. Shannon Elf, a junior investigator at University of Chicago, believes the same can be… Read More »Learning More About MPN Cell Metabolism to Help Identify Novel Points of MPN Therapy

The world of myeloproliferative neoplasms (MPNs) has witnessed a surge in scientific breakthroughs. From detecting genetic drivers as early as in the fetus to the unprecedented pace of new drug approvals, the momentum is changing how this family of blood cancers is understood and managed. Increased attention and industry investment have led to a growing number of treatment… Read More »What’s Next?

We celebrate two members of our Board of Directors recently named MPN Heroes during the Annual Meeting of the American Society of Hematology (ASH). Dr. Andrew Schafer is director of the Richard T. Silver, M.D. MPN Center at Weill Cornell in NYC and a valued scientific advisor to MPN Research Foundation for many years. https://www.youtube.com/watch?v=9_yNLqJKHJU… Read More »Our Own MPN Heroes

Each year at the Annual Meeting of The American Society of Hematology (ASH), there are more MPN research and clinical trial reports. This year, some unique highlights include 16 topics we find notable, along with many others with a potential connection to MPNs.  Artificial intelligence (AI) to differentiate between essential thrombocythemia and prefibrotic primary myelofibrosis. … Read More »MPN news to expect at ASH 2023

Thrive Award Spotlight : Idoroenyi Amanam, MD Using our own immune system to treat cancers has become a reality for many solid and blood cancers. “It’s an ideal therapy, as it’s our own specialized system that helps treat abnormal cells,” according to Idoroenyi Amanam, MD, of City of Hope. For MPNs, there is a need… Read More »Investigation of IL-1RAP in Myeloproliferative Neoplasms: Potential Novel Anti-leukemic Therapy

An MPNRF Patient Impact Council recently launched to actively advocate for the patient voice and perspective in all aspects of our work to promote research advances and therapies with meaningful patient benefits.    Created with very clear objectives and activities, the council includes individuals representing diversity in MPN experiences, diagnosis, skills, community connections, geographic locations, and… Read More »2024-2026 Patient Impact Council Announced